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Repurposing an Old Technique to Track Cell Migration
Into Human Atheroma*Viviany R. Taqueti, MD, MPH,yzx Matthias Nahrendorf, MD, PHD,k Marcelo F. Di Carli, MDyzxA wealth of basic and translational science overthe last 2 decades has harnessed the cellularand molecular mechanisms underlying the
initiation, progression, and complications of athero-
sclerosis (1–4). This progress in our fundamental un-
derstanding of the pathogenesis of atherosclerosis
has provided new opportunities for targeted molecu-
lar imaging (5). Over the last 10 years, much of the
molecular imaging effort in humans has focused on
imaging approaches that target various aspects
of inﬂammation within atherosclerotic plaques (5).
Endothelial cell activation, cell metabolism, phago-
cyte function, proteinase activity, and angiogenesis
are among the most studied molecular imaging targets
in atherosclerosis. Although these approaches provide
a useful cross-sectional snapshot of the targeted
biology within atheroma, they do not allow the direct
study of cell migration to atherosclerotic lesions.SEE PAGE 1019In this issue of the Journal, van der Valk et al.
(6) used labeled white blood cell imaging, a well-
established nuclear medicine technique to assess
inﬂammation/infection in humans, to evaluate trafﬁc
of circulating peripheral blood monocytes (PBMCs)
from the blood stream into human atheroma in vivo.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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dant leukocytes recruited to atherosclerotic lesions
(3). Made in hematopoietic organs, such as the bone
marrow, the number of monocytes in circulation
positively correlates with outcome in cardiovascular
disease (7,8). After entering the arterial wall as
monocytes, these cells differentiate into macro-
phages and play a central role in the progression and
complications of atherosclerotic plaques (3,9). In this
elegant proof-of-concept study, van der Valk et al. (6)
studied 10 patients with prior myocardial infarction,
transient ischemic attack, or stroke with evidence
of atherosclerosis by magnetic resonance imaging
(MRI), all of whom were on statins. They excluded
patients with active systemic inﬂammation, systemic
anti-inﬂammatory drug use, and signiﬁcant renal or
hepatic dysfunction. Five healthy controls without
evidence of cardiovascular disease, and not taking
statins, were balanced to the patients for age, sex,
and body mass index. In each subject, PBMCs were
isolated from peripheral venous blood samples and
subsequently radiolabeled with technetium 99m-
hexamethylpropylene amine oxime (99mTc-HMPAO)
using a clinically approved ready-for-labeling kit.
Radiolabeled autologous PBMCs were then re-infused
into patients, who were imaged with hybrid single-
photon emission computed tomography/computed
tomography (SPECT/CT) at 3, 4.5, and 6 h post-
reinfusion. Labeled PBMC trafﬁcking was assessed
in the carotid arteries and the ascending aorta;
PBMC retention was evaluated by semiquantitative
analysis using conventional arterial-to-blood ratios.
SPECT/CT ﬁndings were correlated with 18ﬂuoro-
deoxyglucose (FDG) PET/CT and MRI, which were
performed at a single time point.
The authors provide in vitro evidence that
the isolation and labeling procedure did not affect
cell viability or PBMC adhesive or transmigratory ca-
pacity. The main ﬁnding is a time-dependent increase
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1031in PBMC accumulation within arterial segments with
MRI evidence of atherosclerosis. The SPECT signal
was signiﬁcantly higher in patients compared to
control subjects. Although the study design did not
allow for immunohistochemical conﬁrmation that the
PBMC signal corresponded to areas of monocyte
accumulation, the fact that peak accumulation of
labeled PBMCs at 6 h correlated with FDG uptake
measured by PET suggests that the imaging signal
corresponded to active areas of vessel wall inﬂam-
mation. Previous studies conﬁrmed that high FDG
PET signal correlates with macrophage burden in
atherosclerotic lesions (10). Nonetheless, the exact
function of these freshly migrated PBMC at arterial
sites correlating with existing atheroma by MRI and
PET cannot be discerned from this study.
Building on preclinical work documenting the use
of labeled monocytes in mice with atherosclerosis
(11), the study by van der Valk et al. is the ﬁrst to
apply this technique in humans. One important
strength and appeal of the study: it employs estab-
lished and approved techniques for labeling and im-
aging PBMCs, thereby providing a potentially useful
approach for clinical monitoring of novel therapeutics
that can modulate monocyte recruitment in human
atherosclerotic lesions. While the work represents a
very important ﬁrst step, several issues need to
be addressed before we can conﬁrm that this tech-
nique provides an effective imaging approach in
human atherosclerosis. First, the study includes only
10 patients with evidence of advanced atheroscle-
rosis by MRI. Although the authors reported a sig-
niﬁcant SPECT signal increase at 6 h post-injection,
there appears to be wide variation among individual
patients, so further studies should be conducted
to conﬁrm the sensitivity of this approach. In a
related issue, there was no additional imaging later
than 6 h after cell injection and we do not know
whether the 6-hour time point captured the peak
monocyte recruitment into atherosclerotic plaques.
Previous work in ApoE-/- mice using a similar imaging
approach but with 111Indium (with a longer w2.8-day
physical half-life) suggested that peak accumulation
of labeled PBMCs occurred at 5 days post-injection
(11). While it is likely that monocyte kinetics differ
in humans, this presents an area for further investi-
gation/optimization of the technique. The need for
later imaging time points may be addressed by
replacing 99mTc for 111In, which is also approved for
clinical use. Additionally, all of the patients, but
none of the controls, were on statins and exhibited
a lower median serum C-reactive protein (CRP) level
than the controls. Thus, the positive and signiﬁcant
correlation between CRP and arterial wall PBMCaccumulation described by the authors may have
been driven by a few patients with extreme CRP
values.
Could targeted monocyte imaging be used as a
surrogate marker of high-risk atherosclerotic plaques
and guide the timing and intensity of new therapeutics
in research trials? The answer to this question will
require considerably more evidence supporting a
pathophysiologic link between trapping of labeled
PBMCs and high-risk features of plaques. While
experimental models of atherosclerosis offer evi-
dence of this link (11), this needs to be evaluated in
humans, ideally comparing the imaging signal to gold
standard histology studies. As mentioned earlier, the
colocalization of PBMCs with areas of increased FDG
signal is both interesting and reassuring. Yet, the
exact function of these freshly migrated PBMCs at
arterial sites correlating with existing atheroma by
MRI and PET cannot be discerned from this study. As
the authors note, PBMCs comprise a heterogeneous
population of cells, some of which may exhibit anti-
inﬂammatory, rather than proinﬂammatory, proper-
ties. Future studies also will have to demonstrate
that this is a potentially modiﬁable imaging target
with existing or novel medical interventions and,
more importantly, that such modiﬁcation leads to
decreased high-risk plaque features and/or improved
clinical outcomes. The fact that statin treatment
of ApoE/ mice can lead to signiﬁcant reduction
(w5-fold) in monocyte recruitment to plaques com-
pared with placebo-treated mice (11) suggests that
monocyte tracking to atherosclerotic plaque may be
a viable imaging alternative for clinical translation,
especially in the setting of clinical trials that aim
to modulate the migration of innate immune cells,
including enhancing the accumulation of regulatory
cells. The approach also could be expanded to
other cells that may contribute to atherosclerosis
pathology, such as lymphocytes.
In summary, the study by van der Valk et al. (6)
provides important preliminary evidence document-
ing the potential of targeted cell imaging for pheno-
typing human atherosclerosis. If conﬁrmed by future
studies, such an approach will expand and comple-
ment our growing armamentarium of structural and
functional imaging techniques and help us capture
new biology and, potentially, enable early diagnosis
and guide management of the disease.
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